drugset
drugset / Trial / NCT01195727

Multiple-Dose Study Apixaban in Pediatric Subjects With an Indwelling Central Venous Catheter

NCT01195727 ↗

Phase 1 Terminated 13 enrolled Bristol-Myers Squibb Pfizer · collab
Non-randomizedParallel-groupOpen-labelOther

Summary

CV185-079 is a multiple dose Apixaban Pharmacokinetics/Pharmacodynamics (PK/PD) study in pediatric subjects. The objective of this study is primarily to study the PK/PD of Apixaban in pediatric subjects with a central venous catheter.

Timeline

Start
2011-07-26
Primary completion
2012-06-14
Completion
2012-07-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Apixaban Small molecule 0.66 mg/m2 Oral
Subject Apixaban Small molecule 1.32 mg/m2 Oral

Indications

venous thromboembolism